Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study of CITI-002 in Patients with Grade 2 and 3 Haemorrhoids

Trial Profile

A Phase 2b Study of CITI-002 in Patients with Grade 2 and 3 Haemorrhoids

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine/hydrocortisone (Primary)
  • Indications Haemorrhoids
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2019 According to a Citius Pharmaceuticals media release, the company announced that the proceeds will be used for this trial.
    • 13 Mar 2018 New trial record
    • 06 Mar 2018 According to a Citius Pharmaceuticals media release, following a Type C meeting with the FDA which included discussion of results of the phase 2a study, the company also requested the Agencys feedback on the phase 2b study design, including target patient population, inclusion/exclusion criteria, and efficacy endpoints.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top